Aditum Bio's Joe Jimenez (L) and Mark Fishman
September 21, 2023 10:57 AM EDT
Financing
Startups
Deals

Af­ter Ver­sa­nis suc­cess, Adi­tum launch­es Celex­or Bio with au­toim­mune drug from Ace­lyrin part­ner In­ma­gene

Kyle LaHucik

Senior Reporter

The biotech li­cens­ing whizzes at Adi­tum Bio, the VC firm from ex-No­var­tis CEO Joe Jimenez and Mark Fish­man, have cre­at­ed their 10th com­pa­ny by nab­bing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump picks vac­cine skep­tic Kennedy to lead HHS, in what would be an up­heaval of US health pol­i­cy

Eu­ro­pean drug reg­u­la­tor re­vers­es opin­ion on Ei­sai and Bio­gen's Alzheimer's drug

Gilead will close Philadel­phia, Seat­tle of­fices as part of job re­duc­tions

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times